Imricor Medical Systems (IMR) H1 2025 earnings summary

Executive summary

• Achieved multiple regulatory milestones, including CE Mark approval for second-generation ablation catheters, diagnostic catheters, capital equipment, and NorthStar Mapping System in Europe, and submission of the second PMA module to the US FDA.

• NorthStar submitted for FDA approval, with U.S. commercialization expected to begin upon approval by year-end; U.S. launch to initially focus on pediatric hospitals.

• Rebuilt and expanded the European sales team, growing the hospital pipeline and establishing Imricor BV in the Netherlands to accelerate R&D and commercialization.

• Expanded clinical trial activity in Europe (visible VT trial) and the U.S. (visible AFL trial), with strong interest from hospitals with MRI capabilities.

• Maintains a strong balance sheet, supported by a recent capital raise and over 11 quarters of funding.

Financial highlights

• Total revenue for H1 2025 was $197,000, down 52% year-over-year, mainly due to lower equipment sales; consumable device sales were flat at $135,000.

• Net loss increased 92% year-over-year to $13.1 million, primarily due to fair value changes in convertible notes and warrants.

• Adjusted net loss (excluding fair value changes and FX) was $9.99 million, up 27% from $7.89 million in the prior period.

• Operating cash outflow for the half was $9.1 million, up $1.1 million year-over-year, with increased R&D and clinical trial expenses.

• Cash balance at period end was $50.3 million, bolstered by a $44.1 million equity raise.

Outlook and guidance

• Expects NorthStar FDA approval and U.S. commercial launch by year-end, with initial focus on pediatric hospitals.

• Anticipates steady progress on regulatory submissions and approvals for additional devices through Q4 2025 and into early 2026.

• European and Middle Eastern commercial pipelines are maturing, with new site activations expected regularly through 2026.

• VT trial data in Europe expected to drive further adoption and support U.S. expansion.

• Management concluded that existing working capital is sufficient to fund operations for at least 12 months from the reporting date.